Delayed results of nonspecific inhalation immunotherapy for atopic asthma with Ruzam

The purpose of the trial was to study the delayed efficiency and safety of therapy with Ruzam (an inhaled formulation) in adult patients with mild and moderate persistent atopic asthma.
The clinical, functional, and laboratory parameters of therapy (basic therapy in combination with Ruzam or placebo) were estimated in 63 patients with asthma 6 months after termination of a 2-week course of therapy. Therapeutic effectiveness was evaluated from the frequency of asthmatic attacks, needs for β2-agonists, the scope of basic therapy, and the degree of asthma symptoms according to patients' self-observation diaries, from peak flowmetry and spirometry readings, ACT scores, the level of allergic inflammatory markers, the values of bronchial hyperresponsiveness, and the frequency of acute respiratory viral infections (ARVI).
Within 6 months after termination of the course of inhaled Ruzam therapy, asthmatic attacks were absent and clinical and functional control remained in 30 (97%) patients. There was a reduction in the total scope of basic therapy: the latter was discontinued in 12 (39%), the dose of the inhaled corticosteroid was halved in 5 (16%). In the control group receiving placebo (n = 32), the frequency of attacks and the level of asthma control remained as before; moreover, the scope of basic therapy could not be reduced; it was increased in 8 (25%) patients. There was a further significant reduction of the level of eosinophil cationic protein in the serum and sputum-induced supernatant, which was found in the Ruzam-treated patients immediately after the termination of the course of inhaled Ruzam therapy. Furthermore, the frequency of ARVI considerably declined in them.

asthma, Ruzam, asthma control, bronchial hyperresponsiveness, eosinophil cationic protein, ACT test, nitric oxide in expired air